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SDiscussion
Dr Ross Bremner (Phoenix, Ariz). Thanks very much, Bryan.
What a great presentation, and thank you for a well-written report.
Your study has attempted to clarify a surgical approach to bron-
choalveolar cell carcinoma (BAC) using this large cohort of pa-
tients from the Surveillance, Epidemiology, and End Results
(SEER) database and from a long time period, from 1998 to
2007. It does suffer from the limitations of the SEER database,
which have already been discussed at this meeting, but I laud
your attempt to try to provide some clarification on how we should
approach these patients.
The term ‘‘BAC’’ was originally coined to describe this lipidic
growth pattern of a well-differentiated noninvasive cancer, and
a paradigm was developed that because these lesions are noninva-
sive and well behaved that we should perform a parenchymal-spar-
ing operation and that wedge resection is actually acceptable.
I would say that probably this is how we mostly approach these le-
sions throughout the United States. This report challenges that and
concludes that a more formal resection, such as lobectomy or for-
mal segmentectomy, is necessary. However, our understanding and
classification of this so-called BAC has changed a lot since 1988,
making interpretation of these data quite difficult. I am quite sure
that your data include some patients that we would now say have
a diagnosis of invasive carcinoma in a background of BAC, which
is really a different disease. Thus, my first question is, can you clar-
ify what you think the pathology is in these patients? As you know,
we now have a more recent classification of adenocarcinoma in
situ, minimally invasive adenocarcinoma, and lipidic-predominant
adenocarcinoma, all of which actually have about 100% 5-year
survival if we resect the tumor. What do you think the pathology
is in this retrospective database? Also, do you think that there is
any way we can try to clarify the pathology? Is there any mecha-
nism where we could go back historically to do that?
Dr Whitson. Yes, answers to some of those questions we can
attempt to obtain from the datawe have available. Somewe cannot.
From what is coded in the SEER registry, you are very correct—it
covers essentially 2 decades worth of data. The predominant cell
type is what is recorded by the registrars and we are unfortunately
left to the registrar’s discretion or the pathologist who interprets
those slides as to what that is and how it is reported. For our eval-
uation, we selected those that were coded as bronchoalveolar as theThe Journal of Thoracic and Capredominant cell type. Those that were mostly adenocarcinoma,
we excluded. However, given the size and span of the registries
over the entire United States, there is sure to be some overlap, de-
pending on who interpreted those slides.
What we could do to try to answer your question about looking
at some of the more recent histologic classifications that came out
through International Association for the Study of Lung Cancer in
the spring, although we cannot go back to these data and say what
is a lepidic growth pattern versus those that are not, we could look
at mucinous histologic findings and those that are nonmucinous
and that might be a way to interpret the invasive mucinous adeno-
carcinomas. That is the extent of the data that we have from the
SEER database.
Dr Bremner. I would submit to you that there is a danger in this
report that the difference that we see between these groups of pa-
tients is that they have included invasive carcinoma, which we
would not include in our current diagnosis of—a term that I think
needs to be dropped, which I think is BAC—a term that we will
soon not be using anymore.
Dr Whitson. I think as we go forward, that term—bronchoal-
veolar carcinoma—is going to go away and you have adenocarci-
noma in situ, invasive mucinous adenocarcinoma, and such. How
these get coded in the SEER database and how we look at things
from an institutional perspective in comparing previous data to
data going forward is going to have to be looked at quite carefully.
Dr Bremner. I imagine that pulmonary function played a role in
the surgeon’s decision to do either wedge or lobectomy. Do you
have any data on the pulmonary function test findings in these
patients?
DrWhitson.No. Unfortunately, no data on pulmonary function
test findings or fitness in the SEER data.
Dr Bremner. Just to reiterate, I worry that we are going to send
a message that patients who have BAC now need to undergo lobec-
tomy when, our current histology and understanding, is that BAC
is really going to be a noninvasive lesion and should be approached
with parenchymal-sparing surgery.
Thanks very much and I am sure this was a fantastic exercise in
lots of statistics.
Dr Whitson. Thank you very much. I would take Dr Bremner
a different perspective. I would not necessarily say that they all
need to undergo lobectomy, but we need to look at that data in con-
cert with some of the data coming from the Cancer and Leukemia
Group B trial about the tumor size. If one had a small lesion, per-
haps wedge resection is adequate—I don’t know, segmentec-
tomy—probably for sure for those less than 2-cm lesions. The
decision would be determined by the cell type and whether it
were a pure histologic type or not. Lymphadenectomies are not be-
ing performed. That might be as much or as more important as per-
forming the anatomic resection just as a surrogate. In theory,
lymph nodes are not important in BAC, but as we have shown
from these data, they do appear to be involved in some fashion.
Dr DouglasWood (Seattle, Wash). I am going to pick up where
Ross left off and also be critical—I am sorry—because I think that
this report, despite being technically very well done, is providing
a dangerous and regressive message that is actually erroneous for
exactly the reasons that Ross just interpreted. Unfortunately, the
SEER database, with which I am very familiar, has no ability to
discriminate between our current definitions of noninvasiverdiovascular Surgery c Volume 143, Number 3 599
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Scarcinoma, which is what BAC in its pure form is, and adenocar-
cinoma with bronchoalveolar features, which is just invasive ade-
nocarcinoma. By definition, pure bronchoalveolar carcinoma is
a noninvasive tumor and therefore it does not have the ability to
develop lymphatic invasion that would involve the lymph nodes;
thus, your whole premise of the extent of lymph node dissection
is not justified and neither is your argument about the extent of pa-
renchymal resection. By definition, a noninvasive cancer does not
have access to the lymphatics and it is not able to spread to the
lymph nodes. Now, you are right that there might be a component
of invasive carcinoma within that apparent bronchoalveolar carci-
noma so there could be the occasional error; however, by our
current better definitions of pathologic analysis of pure bronchoal-
veolar carcinoma or noninvasive tumor, the extent of lymph node
involvement or dissection should not matter. So, I am worried
about the wrong message being delivered when we have become
better at defining a patient population that does not require lobec-
tomy. Others will misinterpret your findings that obviously include
a wide spectrum of invasive carcinoma as potentially pushing us
back toward more aggressive resection for pure bronchoalveolar
carcinoma or noninvasive adenocarcinoma.
Dr Whitson. That is a very good point, and we do need to look
critically at that.
Dr Scott Swanson (Boston, Mass). I liked the report. One ques-
tion about your survival analysis in terms of anatomic or nonana-
tomic. Is that independent of lymph nodes or is that associated with
the nodal removal?
Dr Whitson. Those 4 categories of lymph node evaluation—
you mean for the Kaplan-Meier curve?
Dr Swanson. Yes, when you showed survival by lobectomy
segmentectomy versus wedge. Is that independent of nodal sam-
pling? Is that univariate or multivariate?
Dr Whitson. That was a multivariate analysis, but it was with
the lymph nodes not evaluated as a continuous variable but as those
4 subcategories of 0, 1 to 10, 11 to 16, or greater than 17.
Dr Swanson. So an anatomic resection independent of nodal re-
moval is a better option.600 The Journal of Thoracic and Cardiovascular SurgDr Whitson. Better than a wedge, yes, sir, but given the histo-
logic conversation we just had.
Dr Joseph Shrager (Stanford, Calif). So, the point has been
made several times, I think correctly, that the report does not really
say anything about what used to be called pure bronchioloalveolar
carcinoma. But, it does say something very strong, I think, about
smaller invasive carcinomas or probably what most of us are see-
ing a lot of—which are these tumors that are sort of half ground-
glass and half invasive. The very strong statement that this report
is saying about those tumors is that segmentectomy seems a lot
better than wedge in that situation. Now, we do not know from
your data, the fine points. You know, the Japanese say over and
over that 50% is the cutoff point, that if it is less than 50% invasive,
you can basically do a wedge, and if it is greater than 50% solid on
computed tomography, you cannot. You do not have that degree of
fine hair-splitting here, but I think it is important to make that
point—that segmentectomy is looking a lot better than wedge.
Dr Whitson. We tend to agree with you, Dr Shrager.
Dr Paul Schipper (Portland, Ore). Just a quick comment on
what Doug said. I had the opportunity to read your report, and I
think the methodology is very good, but that one input that you
had, that kind of muddy definition of BACmakes the results some-
thing, maybe, that we cannot use. However, now we have this new
definition of adenocarcinoma in situ and at some point, 5 years
down the road, you are going to be able to take that one and
plug it into this method.We do not have the opportunity of defining
what tumors are going to do. They do what they do, and we sort of
see what happens. I guess I would say that this study would need to
be repeated with that carcinoma in situ population. Just to perhaps
make an analogy, we operate on high-grade dysplasia, and that also
is an in situ lesion, but we know a certain percentage of the time, it
is not. I think it would be worth repeating this in a number of years
looking at carcinoma in situ and not just depending on your pathol-
ogist saying this tumor does not look to be invasive and therefore it
is not going to be in the lymph nodes. We need to see whether that
is in fact the truth.
Dr Whitson. Very good point. Thank you, sir.ery c March 2012
